Clinical efficacy of T-DXd in HER2-positive advanced gastric adenocarcinoma patients was first detected in a phase Ib study, where 44 patients were treated with either 5.4 mg/kg or 6.4 mg/kg of T-DXd [37]. Here, ERBB2 is linked to gastric adenocarcinoma.